CClinicalTrials.gg
Status unknownNCT01211015Updated Sep 29, 2010

Endoplasmic Reticulum Stress in Chronic Respiratory Diseases

An observational study in ER Stress,, Chronic Airway Disorders, and Lung Cancer,, sponsored by Chonbuk National University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-09-29.

Sponsored by Chonbuk National University · Observational

The sponsor has not verified this record recently (last verified Sep 2010), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Aim: To investigate whether ER stress is implicated in the pathogenesis of various pulmonary disorders

Measurement:

  1. Unfolded protein responses (UPRs) in blood (PBMCs)of patients

    1. CHOP
    2. GRP 78 and so on
  2. Unfolded protein responses (UPRs) in blood (PBMCs)of healthy controls

    1. CHOP
    2. GRP 78 and so on
02

Conditions studied

  • ER Stress,
  • Chronic Airway Disorders,
  • Lung Cancer,
  • Interstitial Lung Diseases
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's planned enrollment of 50 is below the median of 157 across 929 observational studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Chonbuk National University is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  1. Control group

    • healthy control (volunteer)
  2. Disease group

    • chronic pulmonary lung diseases including asthma, COPD, ILD, and lung cancer

Inclusion criteria

  • > 18 yrs
  • Definitive diagnosis as chronic pulmonary diseases by physician

Exclusion criteria

Exclusion Criteria:

  • Any other chronic medical illness such as DM, HTN, and other malignancy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control group

    healthy control group

  • Disease group

    asthma, COPD, ILD, lung malignancy

06

Study locations

1 of 1 sites recruiting
  • Chonbuk National University Hospital
    Jeonju, Jeonbuk 561-180, Korea, Republic of
    • Yong Chul Lee, MD, PhD · Contact · leeyc@chonbuk.ac.kr · 82-63-250-1664
    • Yong Chul Lee, MD, PhD · Principal investigator
    • So Ri Kim, MD, PhD · Sub investigator
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01211015
Lead sponsor
Chonbuk National University
First posted
Sep 29, 2010
Start date
Jul 2010
Last update
Sep 29, 2010

Study contacts

Yong Chul Lee, MD, phD
Contact
leeyc@chonbuk.ac.kr
82-63-250-1664 ext. 1664
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion